Maher, T. M., Lancaster, L. H., Jouneau, S., Morrison, L., Lederer, D. J., Molina-Molina, M., … Noble, P. W. (2019). Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Ann Am Thorac Soc, 16(7), 927–930. https://doi.org/10.1513/AnnalsATS.201810-720RL

Maher, Toby M., Lisa H. Lancaster, Stéphane Jouneau, Lake Morrison, David J. Lederer, Maria Molina-Molina, Elisabeth Bendstrup, et al. “Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.” Ann Am Thorac Soc 16, no. 7 (July 2019): 927–30. https://doi.org/10.1513/AnnalsATS.201810-720RL.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, et al. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Ann Am Thorac Soc. 2019 Jul;16(7):927–30.

Maher, Toby M., et al. “Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.” Ann Am Thorac Soc, vol. 16, no. 7, July 2019, pp. 927–30. Pubmed, doi:10.1513/AnnalsATS.201810-720RL.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler K-U, Gilberg F, Axmann J, Petzinger U, Noble PW. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation. Ann Am Thorac Soc. 2019 Jul;16(7):927–930.